SillaJen Inc 215600
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₩2,830.00
- Day Range
- ₩2,770.00–2,855.00
- 52-Week Range
- —–—
- Bid/Ask
- ₩2,805.00 / ₩2,820.00
- Market Cap
- ₩385.10 Bil
- Volume/Avg
- 355,572 / 859,291
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 211.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SillaJen Inc is a Korean based biotechnology company focused on engineering and developing cancer treatment cells. The company along with its subsidiary SillaJen Biotherapeutics, Inc offers Pexa-Vec, an oncolytic virus with antibodies, and improved survival in a randomized trial to cure cancer; and JX929, an engineered vaccinia virus strain that acts on cancer cells by viral attack and subsequent cancer cell oncolysis. SillaJen operates its business activities in Korea and United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 45
- Website
- http://www.sillajen.com
Comparables
Valuation
|
Metric
|
215600
|
298380
|
068270
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 357.35 | 90.78 |
Price/Book Value | 2.80 | 59.47 | 2.42 |
Price/Sales | 211.97 | 45.08 | 12.81 |
Price/Cash Flow | — | — | 50.18 |
Price/Earnings
215600
298380
068270
Financial Strength
|
Metric
|
215600
|
298380
|
068270
|
|---|---|---|---|
Quick Ratio | 7.33 | 1.49 | 0.75 |
Current Ratio | 7.47 | 1.55 | 1.82 |
Interest Coverage | −13.43 | −47.33 | 9.77 |
Quick Ratio
215600
298380
068270
Profitability
|
Metric
|
215600
|
298380
|
068270
|
|---|---|---|---|
Return on Assets (Normalized) | −20.15% | −22.14% | 2.21% |
Return on Equity (Normalized) | −27.58% | −78.54% | 2.72% |
Return on Invested Capital (Normalized) | −22.19% | −30.43% | 2.45% |
Return on Assets
215600
298380
068270
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mjrwmgwg | Stf | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Flhbctl | Vkgxtn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qvvwmnv | Xftclc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kbxhmhmzd | Yxbvml | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Xxmfwndh | Blwv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Lxkfvmndh | Kqxk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Rljjrpyg | Fgkt | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dvkjnwx | Bxz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yxtgfdbxf | Qbcrxw | $13.4 Bil | |||
| Incyte Corp
INCY
| Npznpwxr | Cjsfkdt | $12.7 Bil |
United States